STANFORD CENTER FOR PRECISION MENTAL HEALTH & WELLNESS
(PMHW)

Reimagine Mental Health

 

Our vision is for a precision approach to psychiatry in which neuroscience insights about the human brain are translated into real world clinical care and to improve the quality of individual lives.

 
Burst of Light_edited_edited.jpg

SPOTLIGHT

 
 

OUR RESEARCH

Tracts-3-720x517.jpg

HUMAN CONNECTOME PROJECT FOR DEPRESSION AND ANXIETY

The Human Connectome Project for Depression and Anxiety is transforming our understanding of depression, anxiety and mood disorders based on high resolution imaging of the brain’s connectomes and biotypes.  This study is funded through the NIH Human Connectome Project. It leverages an unparalleled complication of data to achieve never before realized conclusions about the living human brain and how the brain is disrupted in depression and anxiety.

RBRAIN - KETAMINE

Although ketamine has promise as a therapeutic when used at sub-anesthetic doses, we know little about exactly how it impacts the human brain in real time.  In this study we acquire neuroimaging brain scans immediately following infusions of ketamine versus placebo, in a novel mechanistic trial design with healthy individuals. We also acquire detailed information about the individual experiences of each participant so as to connect brain changes to experience. Data from this study is vital to discovering how ketamine works in a more precise way and will inform its safe and personalized therapeutic use in future trials.

p50 center grant figure.tiff
MDMA photo.jpg

RBRAIN - MDMA

We know little about exactly how MDMA – ‘ecstasy’ – impacts the human brain in real time, and how brain changes relate to the experience of MDMA.  In this study we acquire neuroimaging brain scans immediately following doses of MDMA versus placebo, in a novel mechanistic trial design with healthy individuals. We also acquire detailed information about the individual experiences of each participant so as to connect brain changes to experience. Data from this study is vital to discovering how MDMA works in a more precise way and will inform its safe and personalized therapeutic use in future trials.

CATALYST

Through Catalyst, we are developing cutting-edge wearable technology for monitoring stress that is suited to brain health applications. Evidence from our studies connects metrics from the wearable to symptoms and brain imaging biotypes for mental health.

Mentaid1_edited.jpg
Image by Adam Nieścioruk

IRIS NEUROSTUDY

In response to the staggering mental health impact of the COVID-19 pandemic, we have launched the IRIS Neurostudy. This study focuses on improving our understanding of the postinfection impact of SARS-CoV-2 on mental health symptoms and accompanying disruptions to concentration and brain function over a 12-month timeframe.  By better understanding the impact, we can also identify and tailor treatment options.

TMS BIOMARKERS TRIAL

A well-powered multisite clinical trial that aims to advance a biomarker-driven approach to identifying which patients will benefit from transcranial magnetic stimulation (TMS) and through which mechanisms.

tms_website_image.png
 

To sign up for PMHW Announcements click below: